CureSpec Nephrospec

The main articles are:

• Renal failure
• Hypertension (high pressure)

2023: Clinical trials of Nephrospec device to delay dialysis treatment

On September 6, 2023, it was reported that a medical device developed by the Israeli company Curespec is able to delay dialysis treatment of patients with stage three and four chronic kidney disease (CKD) for up to 12 months and is already undergoing clinical trials in hospitals and medical centers in several countries of the world.

A device has been created to delay dialysis treatment for patients with chronic kidney disease

Chronic kidney disease affects about 10% of the world's population, which is just under 800 million people.^[1] At the same time, according to the American National Kidney Foundation (The National Kidney Foundation), 90% of people suffering from this disease do not know about its presence in the early stages, which allows it to progress unnoticed.^[2]

In some cases, CKD is only detected at the "end stage," when the kidneys fail and either transplantation or dialysis is required - a grueling weekly procedure to remove waste and excess fluid from the blood. The average life expectancy of dialysis patients is five years.

According to Curespec CEO Rotem Kaynan, the company hopes that one day Nephrospec will allow CKD patients to abandon dialysis indefinitely.

"Patients with this disease are usually in a state of constant deterioration. We expect that with this treatment they will be in the maintenance stage for as long as possible, "he says.

Nephrospec is an electro-hydraulic acoustic therapy (eHAT) machine equipped with an ultrasonic guidance system. The device is compact and designed for easy implementation in any medical institution. Provides the possibility of non-invasive treatment that helps reduce the need for medical therapy and dialysis procedures.^[3]

Electrohydraulic acoustic therapy is a method of treating acoustic waves of lower intensity than traditional shock wave therapy. eHAT promotes the formation of new blood vessels and restores the function of damaged tissues after six painless treatment sessions over three weeks.

Nephrospec is also promoted as a treatment for hypertension.

"CKD and hypertension go hand in hand," Kainan stressed, adding that hypertension is one of the risk factors for developing kidney problems.

As of September 2023, Curespec is working to validate the effectiveness of the Nephrospec instrument by conducting clinical trials on a larger experimental group. So, for this purpose, the device has already been implemented in the Israeli medical centers Sheba Medical Center and Shaare Zedek Medical Center, as well as in hospitals in Germany, Switzerland and the USA.

"In Israel, at the initial stage, the treatment will be funded by the patients themselves, then by private insurance companies, and will subsequently become part of a basket of medical services fully funded by the health care system," Kainan explained.

If the tests are successful, the devices will remain in the appropriate hospitals as part of the CKD treatment plan.

According to Curespec, the cost of treating hypertension in the world is about $370 billion per year, and the cost of treating dialysis patients is about $100 billion per year. The use of Nephrospec can significantly reduce these costs, according to the company.^[4]

2021: Transfer of Nephrospec development to a separate corporate structure

In November 2021, Medispec, a manufacturer of medical devices, decided to continue further development of Nephrospec within a separate corporate structure - Curespec.

2020: Nephrospec Development Start

The development of the Nephrospec system based on eHAT technology (short for electro-hydraulic acoustic therapy) started in 2020.

Notes